A ray of hope in challenging times: The Budget's impact on cancer treatment and rare diseases.
A much-needed relief for patients and their families.
The recent Budget announcement has brought a glimmer of hope for those battling cancer and rare diseases. By removing basic customs duties on a range of life-saving medications, the government aims to make these treatments more accessible and affordable. This move is particularly significant for patients in Tier 2 and Tier 3 cities, where specialized healthcare is often limited.
But here's where it gets controversial...
The Budget exempts 17 high-cost cancer drugs and seven rare disease medications from customs duties, which typically range from 5% to 11%. This decision is expected to lower the landed cost of these imported drugs, making them more affordable for patients. For instance, therapies like Ribociclib and Venetoclax, which can cost upwards of Rs 20,000 to Rs 1.5 lakh per month, may now become more financially manageable.
And this is the part most people miss...
The Budget also proposes strengthening India's drug regulatory and clinical research ecosystem. By creating a national network of 1,000 accredited clinical trial sites, the government aims to align India's approval processes with global standards. This initiative, coupled with the Biopharma SHAKTI program, is a decisive step towards ensuring regulatory predictability and quality.
However, not everyone is convinced that this indirect measure is enough. Gopa Nair from The Working Group on Access to Medicines and Treatment raises valid concerns. She argues that the government should employ legal tools under the Patents Act, such as compulsory licenses and stricter scrutiny of secondary patents, to improve access to affordable medications. Additionally, streamlining the approval pathway for quality-assured generics and biosimilars could further enhance accessibility.
So, while the Budget's initiatives are a step in the right direction, the debate on ensuring affordable healthcare for all continues. What are your thoughts on this matter? Do you think the government's approach is sufficient, or should they explore alternative strategies to guarantee accessibility and affordability? We'd love to hear your opinions in the comments below!
